It has previously been shown in the P815 murine tumor model that potentially immunogenic tumor cells that express IDO1 are protected from immune-mediated rejection, and that treatment with the IDO-inhibitor 1-MT can revert this effect [9]. This evidence concerns the gene IDO1 and neoplasm.